Congressman Stiver Continues Call for Sensible Patent Reform While there is consensus across Capitol Hill that patent reform legislation is badly needed, the path to achieving a broadly supported bill remains elusive. This is clearly no easy task, as legislators must curb abusive patent practices,…

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, recently testified at the second of three hearings in the Intellectual Property Subcommittee of the Senate Judiciary Committee on the subject of “The State of Patent Eligibility in America.” The hearings are looking at Section 101…

Today, June 19, kicks off The Cultivating Change Summit in Iowa. The three-day event, which is hosted by the Cultivating Change Foundation and sponsored by the Biotechnology Innovation Organization (BIO), will bring together more than 200 agriculture LGBT employees, human resources and diversity…

A new report from BIO and AUTM demonstrates to enormous return on investment that ultimately comes from public funding of early-stage basic research. The licensing of this research has significantly expanded US gross domestic product, industrial gross output, and jobs over the last 22 years.  …

In a much-anticipated move, the Securities and Exchange Commission (SEC) recently proposed a rule to revise the definition of “accelerated” and “large accelerated” filers.  The proposed rule would expand the scope of small public companies that are exempt from the auditor attestation of…

Most new medicines are developed through a process of collaborative licensing agreements or acquisition. Significant negotiations underlie multiple steps of the R&D lifetime for a medicine and potential partners often repeat within a given therapeutic focus or geographic expansion strategy…

In a recent piece for The Washington Post, author Christopher Rowland inaccurately suggested that the federal government has the power to effectively impose price controls over products that have a link to federally-funded research through its patent “march-in” rights under the Bayh-Dole…

BIO represents pioneers in the world’s most innovative industry. It’s our job to support and advocate for our members as they pursue cutting-edge scientific and technological advancements — from finding new ways to treat cancer to enhancing the very food we eat to creating a sustainable environment…

Dr. Gregory Dolin of the Center for Medicine and Law at the University of Baltimore School of Law shared his objections to legislative proposals that falsely link drug costs with patents in an op-ed that ran in The Washington Times this week. As Dolin states, current legislative proposals would…

Dr. Akshaya Shanmugam has always believed that healthcare should be accessible and affordable to everyone and that technology can help deliver that promise. With her strong background in biomedical engineering, she decided to take on a problem facing over 200 million people in the US: addiction. In…